Skip to main content

International Journal of Phytomedicine and Phytotherapy

Table 6 Mortality as relative risk (RR) in placebo controlled cirrhosis trials

From: The potential of silymarin for the treatment of hepatic disorders

Study Duration Dose Silymarin Control (Total mortality) Liver Related Mortality
(Weight) (RR (fixed)) Weight RR (fixed)
(Mo.) mg/day (nt) nL/N (nt) nL/N (%) (95 % CI) % 95 % CI
Ferenci, 1989 [115] 24 420 (28) 18/87 (39) 31/83 (61.79) (0.68 [0.47, 1.00]) 57.29 0.55 [0.34, 0.91]
Trinchet,1989 [132] 3 420 (1) 01 / 57 (3) 03 / 59 (4.56) (0.35 [0.04, 3.22]) 5.32 0.35 [0.04, 3.22]
Bunout,1992 [133] 15 280 (5) 04 / 34 (5) 05 / 37 (7.41) (1.09 [0.34, 3.43]) 8.65 0.87 [0.25, 2.98]
Pares,1998 [116] 24 450 (16) 10/103 (15) 14/97 (23.91) (1.00 [0.53, 1.92]) 26.04 0.67 [0.31, 1.44]
Lucena, 2002 [134] 6 450 (0) 0/30 (1) 1 / 30 (2.32) (0.33 [0.01, 7.87]) 2.71 0.33 [0.01, 7.87]
Total (95 % CI)    (50) 33/311 (63) 54/306 (100) (0.77 [0.56, 1.05]) 100 0.60 [0.40, 0.88]
  1. Total mortality: Test for heterogeneity: Chi2 = 2.12, df = 4 (P = 0.71), I2 = 0 %; Test for overall effect: Z = 1.65 (P = 0.10). Liver Related Mortality: Test for heterogeneity: Chi2 = 0.90, df = 4 (P = 0.92), I2 = 0 %; Test for overall effect: Z = 2.64 (P = 0.008)